Sirolimus
Rapamune (sirolimus) is a small molecule pharmaceutical. Sirolimus was first approved as Rapamune on 1999-09-15. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target peptidyl-prolyl cis-trans isomerase FKBP1A and peptidyl-prolyl cis-trans isomerase FKBP35.
| Trade Name | Rapamune |
|---|---|
| Common Name | Sirolimus |
| Indication | graft rejection, kidney transplantation |
| Drug Class | Immunosuppressives: immunosuppressant, rapamycin derivatives |
